FAP PET/CT for Staging Patients With Breast Cancer
ConditionBreast Cancer Detection
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorOdense University Hospital
About this trial
This study aims to evaluate the clinical utility of \[68Ga\]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer. By targeting fibroblast activation protein (FAP), this novel imaging approach may offer improved tumor visualization compared to conventional imaging, which may help improve treatment planning.
Eligibility criteria
Qualifiers
Male and females ≥ 18 years
Biopsy-verified newly diagnosed breast cancer
Can read and understand Danish
Capable of providing written and informed consent
Disqualifiers
Pregnant or lactating women
Not able to participate in the conduct of the scan due to any reason ( e.g., claustrophobia or inability to lie still for entire imaging time)
Ongoing oncological treatment for another cancer
History of allergic reactions / hypersensitivity attributed to [⁶⁸Ga]Ga-FAP-2286.
Trial design
Treatments tested in this trial
- 68Ga-FAP-2286
Treatment groups
65 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov